315 related articles for article (PubMed ID: 28972043)
1. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
2. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
3. Predicting OncoDx recurrence scores with immunohistochemical markers.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Marginean EC; Robertson SJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):490-6. PubMed ID: 23455176
[TBL] [Abstract][Full Text] [Related]
4. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
Niikura N; Iwamoto T; Masuda S; Kumaki N; Xiaoyan T; Shirane M; Mori K; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Cancer Sci; 2012 Aug; 103(8):1508-12. PubMed ID: 22537114
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850
[TBL] [Abstract][Full Text] [Related]
7. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
12. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Nielsen TO; Parker JS; Leung S; Voduc D; Ebbert M; Vickery T; Davies SR; Snider J; Stijleman IJ; Reed J; Cheang MC; Mardis ER; Perou CM; Bernard PS; Ellis MJ
Clin Cancer Res; 2010 Nov; 16(21):5222-32. PubMed ID: 20837693
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
14. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
Dix-Peek T; Phakathi BP; van den Berg EJ; Dickens C; Augustine TN; Cubasch H; Neugut AI; Jacobson JS; Joffe M; Ruff P; Duarte RAB
Breast Cancer Res Treat; 2023 May; 199(1):1-12. PubMed ID: 36867282
[TBL] [Abstract][Full Text] [Related]
15. Predicting OncoDX recurrence scores with immunohistochemical markers: effect of stromelysin.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Robertson SJ
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):26-30. PubMed ID: 25153499
[TBL] [Abstract][Full Text] [Related]
16. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
[No Abstract] [Full Text] [Related]
17. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
Prat A; Cheang MC; Martín M; Parker JS; Carrasco E; Caballero R; Tyldesley S; Gelmon K; Bernard PS; Nielsen TO; Perou CM
J Clin Oncol; 2013 Jan; 31(2):203-9. PubMed ID: 23233704
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
